|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Graham MV, Purdy JA, Emami B, Harms W,
Bosch W, Lockett MA and Perez CA: Clinical dose-volume histogram
analysis for pneumonitis after 3D treatment for non-small cell lung
cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:323–329. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sterlacci W, Stockinger R, Schmid T,
Bodner J, Hilbe W, Waldthaler C, Oberaigner W, Tzankov A and Fiegl
M: The elderly patient with surgically resected non-small cell lung
cancer-a distinct situation? Exp Gerontol. 47:237–242. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prochazka L, Tesarik R and Turanek J:
Regulation of alternative splicing of CD44 in cancer. Cell Signal.
26:2234–2239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naor D, Sionov RV and Ish-Shalom D: CD44:
Structure, function, and association with the malignant process.
Adv Cancer Res. 71:241–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu H, Tian Y, Yuan X, Liu Y, Wu H, Liu Q,
Wu GS and Wu K: Enrichment of CD44 in basal-type breast cancer
correlates with EMT, cancer stem cell gene profile, and prognosis.
Onco Targets Ther. 9:431–444. 2016.PubMed/NCBI
|
|
7
|
Aso T, Matsuo M, Kiyohara H, Taguchi K,
Rikimaru F, Shimokawa M, Segawa Y, Higaki Y, Umeno H, Nakashima T
and Masuda M: Induction of CD44 variant 9-expressing cancer stem
cells might attenuate the efficacy of chemoradioselection and
worsens the prognosis of patients with advanced head and neck
cancer. PLoS One. 10:e01165962015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang M, Wu J, Lai X, Ai H, Tao Y, Zhu B
and Huang L: CD44 and CD44v6 are correlated with gastric cancer
progression and poor patient prognosis: Evidence from 42 studies.
Cell Physiol Biochem. 40:567–578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sosulski A, Horn H, Zhang L, Coletti C,
Vathipadiekal V, Castro CM, Birrer MJ, Nagano O, Saya H, Lage K, et
al: CD44 splice variant v8-10 as a marker of serous ovarian cancer
prognosis. PLoS One. 11:e01565952016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yikilmaz TN, Dirim A, Ayva ES, Ozdemir H
and Ozkardes H: Clinical use of tumor markers for the detection and
prognosis of bladder carcinoma: A comparison of CD44, cytokeratin
20 and survivin. Urol J. 13:2677–2683. 2016.PubMed/NCBI
|
|
11
|
Jiang H, Zhao W and Shao W: Prognostic
value of CD44 and CD44v6 expression in patients with non-small cell
lung cancer: Meta-analysis. Tumour Biol. 35:7383–7389. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao S, He JL, Qiu ZX, Chen NY, Luo Z,
Chen BJ and Li WM: Prognostic value of CD44 variant exon 6
expression in non-small cell lung cancer: A meta-analysis. Asian
Pac J Cancer Prev. 15:6761–6766. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Situ D, Long H, Lin P, Zhu Z, Wang J,
Zhang X, Xie Z and Rong T: Expression and prognostic relevance of
CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin
Oncol. 136:1213–1219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shinohara S, Hanagiri T, Taira A, Takenaka
M, Oka S, Chikaishi Y, Uramoto H, So T, Yamada S and Tanaka F:
Immunohistochemical expression and serum levels of CD44 as
prognostic indicators in patients with non-small cell lung cancer.
Oncology. 90:327–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li G, Gao Y, Cui Y, Zhang T, Cui R, Jiang
Y and Shi J: Overexpression of CD44 is associated with the
occurrence and migration of non-small cell lung cancer. Mol Med
Rep. 14:3159–3167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su J, Wu S, Wu H, Li L and Guo T: CD44 is
functionally crucial for driving lung cancer stem cells metastasis
through Wnt/β-catenin-FoxM1-twist signaling. Mol Carcinog.
55:1962–1973. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leung EL, Fiscus RR, Tung JW, Tin VP,
Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP: Non-small cell lung
cancer cells expressing CD44 are enriched for stem cell-like
properties. PLoS One. 5:e140622010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roudi R, Madjd Z, Korourian A, Mehrazma M,
Molanae S, Sabet MN and Shariftabrizi A: Clinical significance of
putative cancer stem cell marker CD44 in different histological
subtypes of lung cancer. Cancer Biomark. 14:457–467. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Xiao Z, Wong SK, Tin VP, Ho KY,
Wang J, Sham MH and Wong MP: Lung cancer tumorigenicity and drug
resistance are maintained through ALDH(hi)CD44 (hi) tumor
initiating cells. Oncotarget. 4:1698–1711. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Xie F, Zhang L and Jiang WG: iASPP
is over-expressed in human non-small cell lung cancer and regulates
the proliferation of lung cancer cells through a p53 associated
pathway. BMC Cancer. 10:6942010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sui X, Jiang W, Chen H, Yang F, Wang J and
Wang Q: Validation of the stage groupings in the eighth edition of
the TNM classification for lung cancer. J Thorac Oncol.
12:1679–1686. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo Z, Wu RR, Lv L, Li P, Zhang LY, Hao QL
and Li W: Prognostic value of CD44 expression in non-small cell
lung cancer: A systematic review. Int J Clin Exp Pathol.
7:3632–3646. 2014.PubMed/NCBI
|
|
24
|
Liu Y, Qing H, Su X, Wang C, Li Z and Liu
S: Association of CD44 gene polymorphism with survival of NSCLC and
risk of bone metastasis. Med Sci Monit. 21:2694–2700. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nguyen VN, Mirejovský T, Melinová L and
Mandys V: CD44 and its v6 spliced variant in lung carcinomas:
Relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Neoplasma. 47:400–408. 2000.PubMed/NCBI
|
|
26
|
Afify AM, Tate S, Durbin-Johnson B, Rocke
DM and Konia T: Expression of CD44s and CD44v6 in lung cancer and
their correlation with prognostic factors. Int J Biol Markers.
26:50–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jordan AR, Racine RR, Hennig MJ and
Lokeshwar VB: The role of CD44 in disease pathophysiology and
targeted treatment. Front Immunol. 6:1822015. View Article : Google Scholar : PubMed/NCBI
|
